Browse studies

Find your next paid study

8 recruiting studies matching your filters

Phase 1/Phase 2 Open Label Trial of a Novel Indenoisoquinolone C-MYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatme…

Recurrent GlioblastomaGlioblastoma IDH (Isocitrate Dehydrogenase) WildtypeRelapsed Cancer+12 more

Estimated

~$10 – $5,625

National Institute of Neurological Disorders and Stroke (NINDS)NCT07416188

Phase 1

A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with tacabrutideg in combination wit…

B-cell MalignancyRelapsed CancerRefractory Cancer+1 more

Estimated

~$10 – $7,500

BeOne MedicinesNCT06634589

Observational

Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors

This study is looking to learn whether a tumor testing approach can feasibly measure antibody-drug conjugate (ADC) target proteins in children and young adults…

CNS TumorSolid TumorRelapsed Cancer+2 more

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT07793994

Phase 2

A Phase II Trial Evaluating Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Subjects with relapsed large cell lymphoma will receive 3 cycles of combination therapy consisting of GDP and epcoritamab. Each cycle will last 21 days. GDP co…

Large Cell Lymphoma, DiffuseRelapsed CancerRefractory Cancer

Estimated

~$10 – $7,500

Dipenkumar ModiNCT05852717

Phase 1

A Phase 1/2, Open Label, Study of Roginolisib (IOA-244), an Orally Bioavailable, Selective PI3Kδ Inhibitor in Patients With Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) in Combination With Venetoclax and Rituximab

This research study will test the safety and anticancer activity of the combination of three drugs (Roginolisib, Venetoclax, and Rituximab) for participants wi…

LeukemiaRelapsed LeukemiaChronic Lymphocytic Leukemia+2 more

Estimated

~$10 – $7,500

Jennifer R. Brown, MD, PhDNCT06644183

Phase 2

Zanubrutinib With Pemetrexed for the Treatment of Relapsed/Refractory Primary and Secondary CNS Lymphomas: A Phase II Trial With a Safety Lead-In

This study is being conducted to evaluate the safety and efficacy of the combination of pemetrexed and zanubrutinib (called induction therapy) followed by zanu…

Primary Central Nervous System LymphomaSecondary Central Nervous System LymphomaRelapsed Cancer+1 more

Estimated

~$10 – $7,500

Baptist Health South FloridaNCT05681195

Phase 1

A Phase Ib/II Study of Pembrolizumab, Ibrutinib and Rituximab in Refractory/Relapsed Primary Central Nervous System Lymphoma (PCNSL)

This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL). The t…

Primary Central Nervous System LymphomaRecurrent CancerRefractory Cancer+1 more

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT04421560

Phase 2

A Phase II Study of ISABELA: Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

The main goal of this phase II study is to evaluate the overall response rate of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed …

Relapsed CancerRefractory Multiple MyelomaMultiple Myeloma

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT05922501